StockDrifts LogoStockDrifts

IAM Biologics 493280

Company
아이엠바이오로직스IAM Biologics
Insiders
0
Buys
0
Total Value
—
Avg Return
—
Last Filing
2026-03-20

IAM Biologics (493280) has 0 disclosed insider purchases and 0 disclosed disposals on record, filed by 0 distinct insiders. The earliest filing StockDrifts holds for IAM Biologics is dated 2026-03-20; the most recent is 2026-03-20.

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2026-03-20BUY신규상장
하경식
Ha Kyung-sik
CEO2.4M₩104,000-46.1%₩249.6B ($173.3M)
2026-03-20BUY신규상장
정인수
Insu Jeong
Managing Director13.5K₩104,000-46.1%₩1.4B ($975K)
2026-03-20BUY신규상장
이정민
Jeongmin Lee
Managing Director300.0K₩104,000-46.1%₩31.2B ($21.7M)
2026-03-20BUY신규상장
에이티넘인베스트
Atinum Invest
-1.6M₩104,000-46.1%₩168.7B ($117.2M)

Frequently asked questions

Who has been buying IAM Biologics stock?
0 distinct insiders have filed 0 disclosed insider purchases in IAM Biologics (493280), most recently on 2026-03-20. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does IAM Biologics have?
IAM Biologics has 0 buy-side and 0 sell-side disclosures on record, spanning 2026-03-20 to 2026-03-20.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.